The estimated Net Worth of Stephen C. Glover is at least $292 millier dollars as of 15 June 2021. Mr. Glover owns over 5,882 units of PDS Biotechnology stock worth over $197,749 and over the last 17 years he sold PDSB stock worth over $0. In addition, he makes $94,237 as Independent Chairman of the Board at PDS Biotechnology.
Sign up
Mr. Glover PDSB stock SEC Form 4 insiders trading
Stephen has made over 2 trades of the PDS Biotechnology stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 5,882 units of PDSB stock worth $49,997 on 15 June 2021.
The largest trade he's ever made was buying 80,000 units of PDS Biotechnology stock on 25 June 2007 worth over $63,200. On average, Stephen trades about 6,606 units every 393 days since 2007. As of 15 June 2021 he still owns at least 63,790 units of PDS Biotechnology stock.
You can see the complete history of Mr. Glover stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Glover biography
Stephen C. Glover serves as Independent Chairman of the Board of the Company. Mr. Glover joined PDS’s Board of Directors in April 2019 and is the Chairman of the Board of Directors. Mr. Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, LP, and the Co-Founder, President and CEO of ZyVersa Therapeutics (formerly Variant Pharmaceuticals), a clinical-stage specialty biopharmaceutical company focused on developing drugs to treat inflammatory and renal diseases. Mr. Glover has extensive experience executing biopharmaceutical company turnarounds and growing top line revenues, with a focus on pharmaceutical business strategy corporate development, product development, commercialization and business optimization. His vast experience spans Fortune 100, start up and entrepreneurial environments and his transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management. Prior to co-founding ZyVersa, Mr. Glover was Co-Founder and Chief Business Officer of Coherus BioSciences, a late-stage commercial biologics platform Company focused on delivering biosimilar therapeutics which went public in 2014. Previously, he was President of Insmed Therapeutic Proteins and EVP and Chief Business Officer of Insmed Incorporated, where he was responsible for the creation of the Company’s biosimilar business unit and divestiture of that business to Merck and led the strategic review process that resulted in the merger of Insmed and Transave. Prior to joining Insmed, Mr. Glover held senior-level positions in sales, marketing and operations at Andrx Corporation, Roche Laboratories, Amgen and IMS Health.
What is the salary of Stephen Glover?
As the Independent Chairman of the Board of PDS Biotechnology, the total compensation of Stephen Glover at PDS Biotechnology is $94,237. There are 7 executives at PDS Biotechnology getting paid more, with Frank Bedu-Addo having the highest compensation of $2,583,760.
How old is Stephen Glover?
Stephen Glover is 60, he's been the Independent Chairman of the Board of PDS Biotechnology since 2019. There are 6 older and 6 younger executives at PDS Biotechnology. The oldest executive at PDS Biotechnology Corporation is Richard Sykes, 78, who is the Independent Director.
What's Stephen Glover's mailing address?
Stephen's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Insiders trading at PDS Biotechnology
Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin et Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.
What does PDS Biotechnology do?
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
What does PDS Biotechnology's logo look like?
Complete history of Mr. Glover stock trades at Insmed Inc, PDS Biotechnology et Ambrx Biopharma
PDS Biotechnology executives and stock owners
PDS Biotechnology executives and other stock owners filed with the SEC include:
-
Frank Bedu-Addo,
President, Chief Executive Officer, Director -
Dr. Frank K. Bedu-Addo Ph.D.,
Pres, CEO & Director -
Gregory Conn,
Chief Scientific Officer -
Lauren V. Wood M.D.,
Chief Medical Officer -
Dr. Gregory L. Conn,
Chief Scientific Officer -
Gregory Freitag,
Independent Director -
DeLyle Bloomquist,
Independent Director -
Stephen Glover,
Independent Chairman of the Board -
Richard Sykes,
Independent Director -
Otis Brawley,
Director -
Deanne Randolph,
Investor Relations -
Kamil Ali-Jackson,
Independent Director -
Ilian Iliev,
Director -
Lauren Wood,
Chief Medical Officer -
Michael King,
Interim Chief Financial Officer -
Janetta Trochimiuk,
Controller -
Dr. Mark Baxter Ph.D.,
Sr. VP of Global Quality -
Hillary Yegen,
VP of Legal -
Dr. Joe J. Dervan,
VP of R&D -
Matthew C. Hill CPA,
CFO & Principal Accounting Officer -
Matthew C Hill,
Chief Financial Officer -
James J Loughlin,
Director -
Voorhees Seth Van,
Chief Financial Officer -
Lars Boesgaard,
Chief Financial Officer -
Spencer D. Brown,
Senior VP, General Counsel -
Kirk V. Shepard,
Chief Medical Officer -
Stephan Toutain,
Chief Operations Officer